ClinicalTrials.gg
RecruitingNCT07104812Updated Feb 11, 2026

Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS)

A Phase 2 interventional study of Osilodrostat 1 MG in Mild Autonomous Cortisol Secretion and Autonomous Cortisol Secretion (ACS), sponsored by Mayo Clinic. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-11.

Sponsored by Mayo Clinic · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 58 studies in Cushing Syndrome with a site in United States — 14 open to participants now, 17 under way, none of them phase 3. Cushing Syndrome · United States.

Planned enrollment
27th of 34
15 · median 35
Started
2026
with 4 others
Phase 2
17 of 58
7 open now
Primary completion
2027-01
later than 2 of 16 live
Registered
54th of 58
by date
Lead sponsor
4 of 58
Mayo Clinic

Among the 58 studies in Cushing Syndrome with a site in United States, this one is the 27th largest by planned enrollment of the 34 interventional ones that give a count, is one of 5 that started in 2026, is one of 17 in phase 2, reaches primary completion later than 2 of the 16 other live ones, and was the 54th registered.

Cushing Syndrome

123 studies on the registry are indexed under Cushing Syndrome; 42 are open to participants now.

Browse Cushing Syndrome studies →

Open to participants now

14 of the 58 studies in Cushing Syndrome with a site in United States are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 35 Cushing Syndrome studies recruiting now, 14 (40%) set no upper age limit and 10 (29%) stop at 75 or younger; 8 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Cushing Syndrome with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and tolerability of 1 mg osilodrostat therapy in patients with mild autonomous cortisol secretion (MACS), and to determine the impact on 24h urine steroid metabolome and circadian cortisol/cortisone concentrations

03

Conditions studied

  • Mild Autonomous Cortisol Secretion
  • Autonomous Cortisol Secretion (ACS)

Keywords

  • hypercortisolism
  • cortisol excess
  • Adrenal adenoma
  • Adrenal hyperplasia
  • Cushing Syndrome
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provide written
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Age ≥ 18 years
  • Diagnosed with MACS

    • At least 2 abnormal post-dexamethasone cortisol results:

      i. 1 mg post-dexamethasone cortisol >1.8 mcg/dL or ii. 8 mg post-dexamethasone cortisol >1 mcg/dL

    • Historical dexamethasone suppression test results can be used if performed within 24 months prior to enrollment.
  • Adrenal imaging phenotype consistent with benign disease (adrenal adenoma/s, macronodular or micronodular adrenal hyperplasia)
  • At least one of the following comorbidities:

    • Obesity (>30 kg/m2)
    • Dysglycemia
    • Dyslipidemia
    • Hypertension
    • Osteopenia
    • Osteoporosis
    • Fragility fractures
  • Ability to take oral medication and be willing to adhere to the study intervention regimen
  • For persons of : agreement to remain abstinent (refrain from heterosexual intercourse) or use a method with a failure rate of ≤ 5% per year during the treatment period and for 1 month after the last dose of study treatment.

Exclusion criteria

Exclusion Criteria:

  • Planned alternative therapy for MACS during the study period
  • Current use of oral exogenous therapy
  • Current use of opioid therapy >20 MME/day
  • Planned use of oral exogenous glucocorticoid therapy
  • Planned use of opioid therapy >20 MME/day
  • Use of injectable glucocorticoid within the last 6 weeks or anticipated glucocorticoid use during the study period.
  • Hypokalemia of hypomagnesemia at baseline visit
  • Prolonged on baseline
  • Concomitant therapy with medications likely to lead to drug-drug interactions (based on PI review).
  • Investigator's judgement based on history/physical examination that a comorbidity or concomitant medication may impact the hypothalamic-pituitary-adrenal axis or steroid metabolome
  • Uncontrolled intercurrent illness including, but not limited to:

    • Ongoing or active infection
    • Symptomatic congestive heart failure
    • Unstable angina pectoris
    • Cardiac arrhythmia
    • Psychiatric illness/social situations that would limit compliance with study requirements
  • Pregnancy or lactation
  • Known allergic reactions to osilodrostat
  • Suspected false positive post-dexamethasone cortisol results due to increased metabolism, poor absorption, or noncompliance with dexamethasone.
  • Treatment with another drug or other intervention within lower than specific therapy
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Mild autonomous cortisol secretion (MACS)

    Women and men diagnosed with MACS who are patients at Mayo Clinic.

    Drug: Osilodrostat 1 MG

Interventions

06

What researchers measure

Primary outcomes

  1. Adverse Events

    Number of adverse events

    Time frame: 4 weeks

  2. Adrenal insufficiency

    Number of subjects to experience adrenal insufficiency, defined as combined measurements of cortisol \< 7 mcg/dL and ACTH\>60 pg/dL or single cortisol \< 5 mcg/dL

    Time frame: 4 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2026 (actual). Primary completion is estimated for Jan 2027, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2025
First posted
Aug 5, 2025
StartActual
Jan 14, 2026
Primary completionEst.
Jan 2027
CompletionEst.
Jan 2027
Last update
Feb 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07104812
Lead sponsor
Mayo Clinic
Collaborators
RECORDATI GROUP
Responsible party
Irina Bancos (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Aug 5, 2025
Start date
Jan 14, 2026
Primary completion
Jan 2027 (estimated)
Completion
Jan 2027 (estimated)
Last update
Feb 11, 2026

Study contacts

Irina Bancos, MD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Osilodrostat

Start the discussion